Drug Profile
Velimogene aliplasmid
Alternative Names: Allovectin; Allovectin-7; VCL-1005; VCL-1005-208Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics
- Class Antineoplastics; DNA; Gene therapies; Lipids
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Orofacial cancer; Renal cancer